This year’s ISPE Annual Meeting & Expo will be full of great, thought-provoking content for the Investigational Products Community of Practice.
The theme “Driving Innovation to Advance Patient Therapies” aligns with the Investigational Products track focused on supply chain agility. From driving efficiency in demand modeling through agility in distribution, the topics will invoke discussion amongst Investigation Products professionals as to how we can innovate to meet the demands of the future.
The End to End Supply Chain Management track kicks off on Sunday with the session “Artificial Intelligence: Taking the Mystery Out of Supply Chain Planning”. This session will be followed by a discussion on how to “Leverage Expiry Date Material Planning to Reduce Waste.” Additional sessions that will be featured during the End-to-End Supply Chain Management track include:
We look forward to seeing and networking with all of you at our annual Investigational Products Community of Practice event on Monday Night. It promises to be an exciting evening of Halloween fun as we cruise on a casino game ship reuniting old acquaintances and meeting new ones to continue to strengthen our community.
To learn more about the 2017 ISPE Annual Meeting & Expo and the End-to-End Supply Chain Management sessions offered during the conference, visit the conference website.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...